Spine | InterventionBrochure
Leader Biomedical’s Spine Intervention portfolio offers targeted solutions for treating osteoarthritis, spinal fusion, and adhesion control and prevention.
Please send this document to my inbox
Hyalosyn™ Gel is a 1% sodium hyaluronate viscoelastic solution in a sterile, pre-filled syringe for improved joint mobility with three to five injections (one per week). Hyalosyn™ Gel increases the shock-absorbing capacity of joints and relieves joint pain caused by osteoarthristis, or at first signs of movement limitations and joint pain.
- Manufactured by synthetic fermentation
- No microbiological residues
- Suitable for intra-articular injection into all synovial joints
- Sterile pre-filled syringe for easy injection
- Clinically proven therapy for osteoarthritis for more than 10 years
Adcon® Gel - adhesion control barrier gel
Adcon® Gel is a biocompatible resorbable gel, composed of polyglycan ester combined with absorbable gelatine in a phosphate-buffered saline. Adcon® Gel provides a physical barrier to inter-tissue adhesions and inhibits fibroblast migration and ingrowth. This results in improved patient rehabilitation, reduced recurrent pain, and decreased number of re-operations as a result of such adhesions. The design of Adcon® Gel establishes a temporary basal lamina by combining an absorbable, collagen-derived material with a resorbable polyglycan ester.
- Prevents adhesion formation
- Extensive clinical history
- Ease of use
All Leader Biomedical allografts are processed with our proprietary eCOO® Technology, a mild and eﬃcient platform using supercritical carbon dioxide (scCO2) to clean, sterilise, and impregnate human and animal-derived bone and tissue with limited use of chemicals. For spine intervention treatments, we offer eTiss® cancellous and cortical bone chips with sound structural and mechanical properties for filling of bone loss and/or correcting of defects as well as eTiss® DBM cortical bone demineralised with the goal of exposing encapsulated growth factors, such as bone morphogenetic proteins (BMPs).
Properties of eCOO® allografts
- Macroporous: stimulating cell colonisation and osteoconduction
- Microporous: enabling biologic fluids to pass through the construct
- Bioactive: ensuring the tissue graft interacts with the patient’s body
OssGro® synthetic bone grafts
Leader Biomedical’s OssGro® synthetic bone grafts are produced with MBCP™ Technology, a proprietary method for producing high quality synthetic bone grafts composed of 60% HA and 40% βTCP. For spine intervention treatments, our portfolio offers OssGro® granules (in vial or syringe) and wedges to support new bone formation promoted by the release of calcium and phosphate ions as well as Ossfinity® putty that combines OssGro® granules and an absorbable hydrogel to create a putty, which acts as a carrier for rapid vascularisation and mineralisation.
The MBCP™ advantage:
- Porosity (macro and micro)